Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics

被引:0
作者
Mahmood, Iftekhar [1 ]
Li, Zhaoyang [1 ]
机构
[1] Takeda Dev Ctr America Inc, Clin Pharmacol & Early Clin Dev, Cambridge, MA 02142 USA
关键词
immunoglobulins; obesity; pediatric; pharmacokinetics; pregnancy; primary immunodeficiencies; INTRAVENOUS IMMUNOGLOBULIN; CLINICAL-PHARMACOLOGY; GAMMA-GLOBULIN; FC-RECEPTOR; BODY-WEIGHT; MANAGEMENT; CATABOLISM; DIAGNOSIS; INFUSION; MODEL;
D O I
10.1080/1750743X.2024.2382081
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunoglobulin G (IgG) therapies have been used for decades as standard treatment for patients with primary antibody deficiencies. Monitoring the pharmacokinetics (PK) of IgG is a key component in guiding treatment regimens. Despite the wealth of clinical experience, substantial gaps exist in our understanding of the true nature of IgGs and their disposition in humans. Furthermore, intrinsic and extrinsic factors may alter the PK of IgG, necessitating an individualized approach for patients. A comprehensive literature review was performed in order to summarize the PK of IgGs, examine the mechanisms of IgG disposition (including catabolism), outline considerations for special patient populations and discuss knowledge gaps and future perspectives for improving our understanding of IgG PK in relation to the individualized treatment paradigm.
引用
收藏
页码:879 / 894
页数:16
相关论文
共 93 条
  • [1] Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?
    Abolhassani, Hasssan
    Asgardoon, Mohammad Hossein
    Rezaei, Nima
    Hammarstrom, Lennart
    Aghamohammadi, Asghar
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (11) : 1229 - 1243
  • [2] Aksu G, 2006, TURKISH J PEDIATR, V48, P19
  • [3] Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders
    Ameratunga, Rohan
    [J]. ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2017, 13
  • [4] [Anonymous], CUTAQUIG IMMUNE GLOB
  • [5] [Anonymous], GAMMAPLEX 10 IMMUNE
  • [6] [Anonymous], 2022, The state of obesity: Better policies for a healthier America
  • [7] [Anonymous], DARZALEX FASPRO DARA
  • [8] [Anonymous], 2014, Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products
  • [9] [Anonymous], IDF DIAGNOSTIC CLIN
  • [10] [Anonymous], HYQVIA IMMUNE GLOBUL